Vyome Holdings, Inc
Business
Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company developing next-generation therapeutic solutions for immune-inflammatory and rare diseases. The company's lead program, VT-1953, is a topical gel in development for malignant fungating wounds in advanced cancer patients, with positive Phase 2 results. VT-1908 is an ophthalmic drops program for steroid-sparing anterior uveitis treatment, and VB-1953 is a Phase 3-ready topical treatment for moderate to severe acne. The company also commercializes reformulated antifungal products in India through a licensing agreement with Sun Pharma, leveraging the US-India innovation corridor.
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 319,714 | 256,944 | — | — | — | |
| Cost of goods sold | −100,943 | −61,974 | 3 | 4 | 5 | |
| Gross profit | 218,771 | 194,970 | 6 | 7 | 8 | |
| Depreciation and amortization | 11,985 | 17,347 | — | — | — | |
| Selling, general and administrative | 2 | 898,572 | 8 | 14 | 9 | |
| Research and development | 588,258 | 285,391 | 2 | 3 | 2 | |
| Transactional fees | 8 | — | — | — | — | |
| Total operating expenses | 11 | 1 | 21 | 53 | 66 | |
| Operating loss | −10 | −1 | −15 | −46 | −58 | |
| Interest expense | −146,641 | −206,004 | — | — | — | |
| Other income(loss), net | 90,987 | 3,814 | — | — | — | |
| Fair value adjustment | 30,511 | −238,931 | −4 | — | — | |
| Total other income (expense), net | −25,143 | −441,121 | — | — | — | |
| Net loss | −10 | −1 | — | — | — | |
| Net loss attributable to non-controlling interest | −215,706 | — | — | — | — | |
| Net loss attributable to owners of Vyome Holdings, Inc. | −10 | −1 | −11 | — | — | |
| Foreign currency translation adjustments | −25,694 | 1,127 | — | — | — | |
| Total comprehensive loss | −11 | −1 | — | — | — | |
| Loss per share basic (in Dollars per share) | −4.86 | −6,001 | −110.87 | −108.9 | −288.97 | |
| Loss per share diluted (in Dollars per share) | −4.86 | −6,001 | −110.87 | −108.9 | −288.97 | |
| Weighted average number of shares outstanding basic (in Shares) | 2 | 241 | 102,707 | 424,390 | 218,522 | |
| Weighted average number of shares outstanding diluted (in Shares) | 2 | 241 | 102,707 | 424,390 | 218,522 |
Consolidated Balance Sheet
| Concept | Trend | FY 2026 2026-12-31 | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | — | 5 | 101,904 | 4 | 4 | |
| Deferred offering costs | — | — | 111,415 | — | — | |
| Prepaid expenses | — | 336,687 | 9,039 | — | — | |
| Other current assets | — | 119,301 | 79,688 | — | — | |
| Total current assets | — | 5 | 302,046 | 10 | 10 | |
| Property and equipment, net | — | 46,393 | 59,179 | 60,000 | 698,000 | |
| Intangible asset - shell company | — | 314,191 | 314,191 | — | — | |
| Goods and service tax and other credits receivable | — | 601,537 | 646,758 | — | — | |
| Prepaid insurance long term portion | — | 67,307 | — | — | — | |
| Right-of-use of asset, net | — | 29,428 | 59,387 | 250,000 | 171,000 | |
| Total non-current assets | — | 1 | 1 | — | — | |
| Total assets | — | 6 | 1 | 11 | 11 | |
| Accounts payable and accrued expenses | — | 1 | 965,607 | — | — | |
| Due to Affiliates | — | 204,562 | 129,346 | — | — | |
| Operating lease liability - current portion | 31,258 | 31,258 | 28,024 | 111,000 | 171,000 | |
| Salary and post-employment benefits payable | — | 870,822 | 919,440 | — | — | |
| Other current liabilities | — | 341,835 | 107,937 | — | — | |
| Convertible debt - current portion | — | — | 4 | — | — | |
| Total current liabilities | — | 3 | 6 | 4 | 7 | |
| Operating lease liability - net of current portion | — | — | 32,830 | 151,000 | — | |
| Total non-current liabilities | — | — | 32,830 | — | — | |
| Total liabilities | — | 3 | 6 | 4 | 7 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Common stock, 300,000,000 VHI shares authorized, 5,919,337 and 0 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | 5,919 | — | — | 1,000 | |
| Preferred stock of VTI, 16,000,000 shares authorized, 0 and 3,076 shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — | 3 | — | — | |
| Additional paid in capital | — | 90 | 51 | 642 | 628 | |
| Non-controlling interest in VTI; 20,000,000 common shares authorized, 1,481,598 and 386 shares issued and outstanding at December 31, 2025 and December 31, 2024 | — | 1 | 1 | — | — | |
| Accumulated deficit | — | −88 | −55 | −636 | −624 | |
| Accumulated other comprehensive loss | — | −78,864 | −53,170 | −88,000 | −88,000 | |
| Total stockholders equity (deficit) | — | 4 | −4 | −6 | — | |
| Total liabilities and stockholders equity (deficit) | — | 6 | 1 | 11 | 11 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| (Gain) loss on fair value adjustment of convertible debt | −30,511 | 238,931 | — | — | — | |
| Non-cash accrued interest expense | 130,659 | 186,659 | — | — | — | |
| Stock compensation expense - stock options | 577,128 | — | 766,000 | 2 | 12 | |
| Stock compensation expense common stock | 6 | — | — | — | — | |
| Prepaid expenses and other current assets | −434,568 | 64,463 | −172,000 | 1 | −76,000 | |
| Other assets | 75,982 | 78,742 | — | — | — | |
| Accounts payable and accrued expenses | 171,342 | −58,861 | −3 | 448,000 | −1 | |
| Due to Affiliates | 75,216 | 95,972 | — | — | — | |
| Post employment benefits | −48,618 | 197,935 | — | — | — | |
| Other liabilities | 200,551 | 12,137 | — | — | — | |
| Net cash used in operating activities | −4 | −614,136 | −17 | −22 | −15 | |
| Net proceeds from sale of fixed assets | — | 315 | — | — | — | |
| Net cash used in investing activities | — | 315 | −10,000 | −92,000 | 2 | |
| Proceeds from issuance of convertible debt | 191,253 | 667,009 | — | — | — | |
| Proceeds from promissory note issued by Reshape | 600,000 | — | — | — | — | |
| Proceeds from sale of common stock pursuant to ATM | 1 | — | 13 | 639,000 | — | |
| Proceeds from sale of common stock under Concurrent Financing, net of costs of $100,000 and deferred offering costs of $111,415 | 7 | — | — | — | — | |
| Proceeds from exercise of warrants | 6,009 | — | 4 | 2 | 46 | |
| Advance from affiliates | — | 30,942 | — | — | — | |
| Net cash provided by financing activities | 9 | 697,951 | 18 | 3 | 33 | |
| Effect of exchange rate changes on cash and cash equivalents | −25,694 | 1,127 | — | 4,000 | 29,000 | |
| Net increase in cash and cash equivalents | 5 | 85,257 | 604,000 | −19 | 20 | |
| Shares issued in settlement of liability to vendor | — | 2 | — | — | — | |
| Exchange of accrued fees to director for stock options | — | 450,000 | — | — | — | |
| Exchange of accrued compensation for stock options | — | 665,232 | — | — | — | |
| Incremental fair value of exchange of VTI preferred shares for new series of VTI preferred shares | 19 | — | — | — | — | |
| Conversion of preferred shares of VTI to common stock of VTI | 1,242 | — | — | — | — | |
| Net liabilities assumed upon Merger with Reshape | 149,735 | — | — | — | — | |
| Conversion of debt into common stock | 4 | — | — | — | — | |
| Fair value of issuance of warrants to preferred shareholders | 2 | — | — | — | 97,000 | |
| Reclass of deferred offering costs to additional paid in capital | 111,415 | — | — | — | — | |
| Exchange of entitlement shares for common shares of VHI | 29,572 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Vyome Holdings, Inc's CIK number?
Vyome Holdings, Inc's SEC CIK number is 0001427570 (1427570). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Vyome Holdings, Inc's SEC filings?
All of Vyome Holdings, Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Vyome Holdings, Inc last report earnings?
Vyome Holdings, Inc (HIND) most recently filed an earnings 8-K with the SEC on May 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-062458). This is Vyome Holdings, Inc's most recent earnings filing of record — not a forecast of its next earnings date.
What is Vyome Holdings, Inc's most recent earnings 8-K?
Vyome Holdings, Inc's latest earnings 8-K (Item 2.02) was filed May 29, 2026 under accession 0001213900-26-062458. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Vyome Holdings, Inc's latest earnings 8-K →
Look up any company's CIK number →